Search

Your search keyword '"Mokuolu, Olugbenga A"' showing total 250 results
Start Over Author "Mokuolu, Olugbenga A"
250 results on '"Mokuolu, Olugbenga A"'

6. Severe malaria intervention status in Nigeria: workshop meeting report.

Author

Shekarau, Emmanuel, Uzoanya, Miriam, Ogbulafor, Nnenna, Ntadom, Godwin, Ijezie, Simon Ntomchukwu, Uzoanya, Miriam Ihuoma, Seye, Babatunde, Fashanu, Chizoba, Eze, Nwamaka, Nwidae, Lekia, Mokuolu, Olugbenga, Nwokenna, Uchenna, Nglass, Iniabasi, Ishola-Gbenla, Olusesan, Okouzi, Methodius, Fagbola, Motunrayo, Oresanya, Olusola, Getachew, Dawit, Chukwumerije, Jennifer, and Erinle, Victoria

Subjects
MALARIA, ADULT education workshops, ELECTRONIC health records, CHILD death
Abstract

Nigeria accounts for 39% of global malaria deaths in children under 5 years of age and the effective management of severe malaria is a health priority. The Annual Nigeria Severe Malaria Stakeholders Workshop, held on the 5–6th of July 2023 in Abuja, Nigeria brought together representatives from 36 States, the Federal Capital Territory, and other key stakeholders to address the management of severe malaria across all levels of the health service. Aims were to provide updates and review progress on severe malaria activities, the burden of disease, commodity logistics management, and pre-referral national policy implementation as well as to disseminate research findings. Two roundtable discussions were conducted to identify the challenges, barriers, and facilitators to the effective management of severe malaria in Nigeria. A key challenge was the limited awareness of updated guidelines and strategic documents among frontline health workers, leading to the misuse of non-recommended medications, like α-β-arteether. Further to this, the need to ensure appropriate treatments during pregnancy and the adoption of the WHO directive on the use of rectal artesunate were highlighted. To address these issues, innovative dissemination channels for guideline awareness were recommended and collaboration with professional organizations to enrich training materials emphasized. Other areas for improvement considered the processes involved in severe malaria management, with insufficient coordination among government agencies, inadequate referral linkages, and inadequate human resources identified as barriers. Recommendations focused on practical measures to minimize wastage of injectable artesunate, enhance data management through scaling up electronic medical records, and strengthen referral systems. The extension of severe malaria surveillance to patients older than 5 years was also proposed. To deliver these changes, actionable plans for sustained recruitment and training are needed, as well as committed advocacy at all levels to ensure timely fund disbursement and institutional support. A key overarching theme from the workshop was that a multifaceted approach was needed to address severe malaria in Nigeria, emphasizing collaborative efforts, evidence-based practices, and strategic resource allocation. With the largest malaria burden globally, the potential impact of addressing the challenges of severe malaria management in Nigeria cannot be understated and must be urgently addressed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Genetic diversity and population structure of Plasmodium falciparum in Nigeria: insights from microsatellite loci analysis

Author

Ajogbasile, Fehintola V., Kayode, Adeyemi T., Oluniyi, Paul E., Akano, Kazeem O., Uwanibe, Jessica N., Adegboyega, Benjamin B., Philip, Courage, John, Oluwagboadurami G., Eromon, Philomena J., Emechebe, George, Finimo, Finimo, Ogbulafor, Nnenna, Jiya, Nma, Okafor, Uche, Ambe, Jose, Wammanda, Robinson D., Oguche, Stephen, Mokuolu, Olugbenga A., Sowunmi, Akintunde, Folarin, Onikepe A., and Happi, Christian T.

Published
2021
Full Text
View/download PDF

11. A framework for stakeholder engagement in the adoption of new antimalarial treatments in Africa: a case study of Nigeria

Author

Mokuolu, Olugbenga, primary, Bolarinwa, Oladimeji Akeem, additional, Opadiran, Oluwatumobi Racheal, additional, Ameen, Hafsat Abolore, additional, Tindana, Paulina, additional, Haan, Freek de, additional, Dhorda, Mehul, additional, Cheah, Phaik Yeong, additional, Amaratunga, Chanaki, additional, and Dondorp, Arjen M., additional

Published
2023
Full Text
View/download PDF

13. Design, Implementation, and Coordination of Malaria Therapeutic Efficacy Studies in Nigeria in 2018

Author

Olukosi, Adeola Yetunde, primary, Musa, Adesola Zaidat, additional, Ogbulafor, Nnenna, additional, Aina, Oluwagbemiga, additional, Mokuolu, Olugbenga, additional, Oguche, Stephen, additional, Wammanda, Robinson, additional, Okafor, Henrietta, additional, Ekama, Sabdat Ozichu, additional, David, Agatha Nkiru, additional, Happi, Christian Tientcha, additional, Ozor, Lynda, additional, Babatunde, Seye, additional, Ijezie, Simon N., additional, Uhomoibhi, Perpetua E., additional, Awolola, Samson Taiwo, additional, Mohammed, Audu Bala, additional, and Salako, Babatunde Lawal, additional

Published
2023
Full Text
View/download PDF

15. Pf7: an open dataset of Plasmodium falciparum genome variation in 20,000 worldwide samples

Author

Abdel Hamid, Muzamil Mahdi, Abdelraheem, Mohamed Hassan, Acheampong, Desmond Omane, Ahouidi, Ambroise, Ali, Mozam, Almagro-Garcia, Jacob, Amambua-Ngwa, Alfred, Amaratunga, Chanaki, Amenga-Etego, Lucas, Andagalu, Ben, Anderson, Tim, Andrianaranjaka, Voahangy, Aniebo, Ifeyinwa, Aninagyei, Enoch, Ansah, Felix, Ansah, Patrick, Apinjoh, Tobias, Arnaldo, Paulo, Ashley, Elizabeth, Auburn, Sarah, Awandare, Gordon, Ba, Hampate, Baraka, Vito, Barry, Alyssa, Bejon, Philip, Bertin, Gwladys, Boni, Maciej, Borrmann, Steffen, Bousema, Teun, Bouyou-Akotet, Marielle, Branch, Oralee, Bull, Peter, Cheah, Huch, Chindavongsa, Keobouphaphone, Chookajorn, Thanat, Chotivanich, Kesinee, Claessens, Antoine, Conway, David, Corredor, Vladimir, Courtier, Erin, Craig, Alister, d'Alessandro, Umberto, Dama, Souleymane, Day, Nicholas, Denis, Brigitte, Dhorda, Mehul, Diakite, Mahamadou, Djimde, Abdoulaye, Dolecek, Christiane, Dondorp, Arjen, Doumbia, Seydou, Drakeley, Chris, Drury, Eleanor, Duffy, Patrick, Echeverry, Diego, Egwang, Thomas, Enosse, Sonia Maria Mauricio, Erko, Berhanu, Fairhurst, Rick, Faiz, Abdul, Fanello, Caterina, Fleharty, Mark, Forbes, Matthew, Fukuda, Mark, Gamboa, Dionicia, Ghansah, Anita, Golassa, Lemu, Goncalves, Sonia, Harrison, G, Healy, Sara Anne, Hendry, Jason, Hernandez-Koutoucheva, Anastasia, Hien, Tran Tinh, Hill, Catherine, Hombhanje, Francis, Hott, Amanda, Htut, Ye, Hussein, Mazza, Imwong, Mallika, Ishengoma, Deus, Jackson, Scott, Jacob, Chris, Jeans, Julia, Johnson, Kimberly, Kamaliddin, Claire, Kamau, Edwin, Keatley, Jon, Kochakarn, Theerarat, Konate, Drissa, Konaté, Abibatou, Kone, Aminatou, Kwiatkowski, Dominic, Kyaw, Myat, Kyle, Dennis, Lawniczak, Mara, Lee, Samuel, Lemnge, Martha, Lim, Pharath, Lon, Chanthap, Loua, Kovana, Mandara, Celine, Marfurt, Jutta, Marsh, Kevin, Maude, Richard James, Mayxay, Mayfong, Maïga-Ascofaré, Oumou, Miotto, Olivo, Mita, Toshihiro, Mobegi, Victor, Mohamed, Abdelrahim Osman, Mokuolu, Olugbenga, Montgomery, Jaqui, Morang'A, Collins Misita, Mueller, Ivo, Murie, Kathryn, Newton, Paul, Ngo Duc, Thang, Nguyen, Thuy, Nguyen, Thuy-Nhien, Nguyen Thi Kim, Tuyen, Nguyen Van, Hong, Noedl, Harald, Nosten, François, Noviyanti, Rintis, Ntui, Vincent Ntui-Njock, Nzila, Alexis, Ochola-Oyier, Lynette Isabella, Ocholla, Harold, Oduro, Abraham, Omedo, Irene, Onyamboko, Marie, Ouedraogo, Jean-Bosco, Oyebola, Kolapo, Oyibo, Wellington Aghoghovwia, Pearson, Richard, Peshu, Norbert, Phyo, Aung, Plowe, Christopher, Price, Ric, Pukrittayakamee, Sasithon, Quang, Huynh Hong, Randrianarivelojosia, Milijaona, Rayner, Julian, Ringwald, Pascal, Rosanas-Urgell, Anna, Rovira-Vallbona, Eduard, Ruano-Rubio, Valentin, Ruiz, Lastenia, Saunders, David, Shayo, Alex, Siba, Peter, Simpson, Victoria, Sissoko, Mahamadou, Smith, Christen, Su, Xin-Zhuan, Sutherland, Colin, Takala-Harrison, Shannon, Talman, Arthur, Tavul, Livingstone, Thanh, Ngo Viet, Thathy, Vandana, Thu, Aung Myint, Toure, Mahamoudou, Tshefu, Antoinette, Verra, Federica, Vinetz, Joseph, Wellems, Thomas, Wendler, Jason, White, Nicholas, Whitton, Georgia, Yavo, William, van der Pluijm, Rob, MalariaGEN, University of Khartoum, University of Cape Coast [Ghana], Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD), The Wellcome Trust Sanger Institute [Cambridge], London School of Hygiene and Tropical Medicine [Fajara, Gambia], London School of Hygiene and Tropical Medicine (LSHTM), National Institute of Allergy and Infectious Diseases [Bethesda] (NIAID-NIH), National Institutes of Health [Bethesda] (NIH), West African Centre for Cell Biology of Infectious Pathogens [Legon, Ghana] (WACCBIP), University of Ghana, Navrongo Health Research Centre [Navrongo, Ghana] (NHRC), Kenya Medical Research Institute (KEMRI), Texas Biomedical Research Institute [San Antonio, TX], Université d'Antananarivo, University of Buéa, Instituto Nacional de Saude [Maputo, Mozambique] (INS), Centre for Tropical Medicine and Global Health [Oxford, UK], Nuffield Department of Medicine [Oxford, UK] (Big Data Institute), University of Oxford-University of Oxford, Mahidol Oxford Tropical Medicine Research Unit (MORU), University of Oxford-Mahidol University [Bangkok]-Wellcome Trust, Menzies School of Health Research [Australia], Charles Darwin University [Australia], Nuffield Department of Clinical Medicine [Oxford], University of Oxford, Institut de Recherche pour le Développement (IRD), Laboratory of Pathogen and Host Immunity [Montpellier] (LPHI), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle (MIVEGEC), and Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud])-Université de Montpellier (UM)

Subjects
data resource, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], plasmodium falciparum, genomics, malaria, Medicine (miscellaneous), genomic epidemiology, General Biochemistry, Genetics and Molecular Biology, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Contains fulltext : 291985.pdf (Publisher’s version ) (Open Access) We describe the MalariaGEN Pf7 data resource, the seventh release of Plasmodium falciparum genome variation data from the MalariaGEN network. It comprises over 20,000 samples from 82 partner studies in 33 countries, including several malaria endemic regions that were previously underrepresented. For the first time we include dried blood spot samples that were sequenced after selective whole genome amplification, necessitating new methods to genotype copy number variations. We identify a large number of newly emerging crt mutations in parts of Southeast Asia, and show examples of heterogeneities in patterns of drug resistance within Africa and within the Indian subcontinent. We describe the profile of variations in the C-terminal of the csp gene and relate this to the sequence used in the RTS,S and R21 malaria vaccines. Pf7 provides high-quality data on genotype calls for 6 million SNPs and short indels, analysis of large deletions that cause failure of rapid diagnostic tests, and systematic characterisation of six major drug resistance loci, all of which can be freely downloaded from the MalariaGEN website.

Published
2023

16. Declining responsiveness of childhood Plasmodium falciparum infections to artemisinin-based combination treatments ten years following deployment as first-line antimalarials in Nigeria

Author

Sowunmi, Akintunde, Ntadom, Godwin, Akano, Kazeem, Ibironke, Folasade O., Ayede, Adejumoke I., Agomo, Chimere, Folarin, Onikepe A., Gbotosho, Grace O., Happi, Christian, Oguche, Stephen, Okafor, Henrietta U., Meremikwu, Martin, Agomo, Philip, Ogala, William, Watila, Ismaila, Mokuolu, Olugbenga, Finomo, Finomo, Ebenebe, Joy C., Jiya, Nma, Ambe, Jose, Wammanda, Robinson, Emechebe, George, Oyibo, Wellington, Useh, Francis, Aderoyeje, Temitope, Dokunmu, Titilope M., Alebiosu, Omobolaji T., Amoo, Sikiru, Basorun, Oluwabunmi K., Wewe, Olubunmi A., Okafor, Chukwuebuka, Akpoborie, Odafe, Fatunmbi, Bayo, Adewoye, Elsie O., Ezeigwe, Nnenna M., and Oduola, Ayoade

Published
2019
Full Text
View/download PDF

18. Parasite reduction ratio one day after initiation of artemisinin-based combination therapies and its relationship with parasite clearance time in acutely malarious children

Author

Akano, Kazeem, Ntadom, Godwin, Agomo, Chimere, Happi, Christian T., Folarin, Onikepe A., Gbotosho, Grace O., Mokuolu, Olugbenga, Finomo, Finomo, Ebenebe, Joy C., Jiya, Nma, Ambe, Jose, Wammanda, Robinson, Emechebe, George, Basorun, Oluwabunmi K., Wewe, Olubunmi A., Amoo, Sikiru, Ezeigwe, Nnenna, Oguche, Stephen, Fatunmbi, Bayo, and Sowunmi, Akintunde

Published
2018
Full Text
View/download PDF

19. A framework for stakeholder engagement in the adoption of new antimalarial treatments in Africa: a case study of Nigeria

Author

Mokuolu, Olugbenga Ayodeji, primary, Bolarinwa, Oladimeji Akeem, additional, Opadiran, Oluwatumobi Racheal, additional, Ameen, Hafsat Abolore, additional, Dhorda, Mehul, additional, Cheah, Phaik Yeong, additional, Amaratunga, Chanaki, additional, Haan, Freek, additional, Tindana, Paulina, additional, and Dondorp, Arjen M., additional

Published
2022
Full Text
View/download PDF

20. Pf7: an open dataset of Plasmodium falciparum genome variation in 20,000 worldwide samples

Author

MalariaGEN, Abdel Hamid, Muzamil Mahdi, Abdelraheem, Mohamed Hassan, Acheampong, Desmond Omane, Ahouidi, Ambroise, Ali, Mozam, Almagro-Garcia, Jacob, Amambua-Ngwa, Alfred, Amaratunga, Chanaki, Amenga-Etego, Lucas, Andagalu, Ben, Anderson, Tim, Andrianaranjaka, Voahangy, Aniebo, Ifeyinwa, Aninagyei, Enoch, Ansah, Felix, Ansah, Patrick O, Apinjoh, Tobias, Arnaldo, Paulo, Ashley, Elizabeth, Auburn, Sarah, Awandare, Gordon A, Ba, Hampate, Baraka, Vito, Barry, Alyssa, Bejon, Philip, Bertin, Gwladys I, Boni, Maciej F, Borrmann, Steffen, Bousema, Teun, Bouyou-Akotet, Marielle, Branch, Oralee, Bull, Peter C, Cheah, Huch, Chindavongsa, Keobouphaphone, Chookajorn, Thanat, Chotivanich, Kesinee, Claessens, Antoine, Conway, David J, Corredor, Vladimir, Courtier, Erin, Craig, Alister, D'Alessandro, Umberto, Dama, Souleymane, Day, Nicholas, Denis, Brigitte, Dhorda, Mehul, Diakite, Mahamadou, Djimde, Abdoulaye, Dolecek, Christiane, Dondorp, Arjen, Doumbia, Seydou, Drakeley, Chris, Drury, Eleanor, Duffy, Patrick, Echeverry, Diego F, Egwang, Thomas G, Enosse, Sonia Maria Mauricio, Erko, Berhanu, Fairhurst, Rick M, Faiz, Abdul, Fanello, Caterina A, Fleharty, Mark, Forbes, Matthew, Fukuda, Mark, Gamboa, Dionicia, Ghansah, Anita, Golassa, Lemu, Goncalves, Sonia, Harrison, GL Abby, Healy, Sara Anne, Hendry, Jason A, Hernandez-Koutoucheva, Anastasia, Hien, Tran Tinh, Hill, Catherine A, Hombhanje, Francis, Hott, Amanda, Htut, Ye, Hussein, Mazza, Imwong, Mallika, Ishengoma, Deus, Jackson, Scott A, Jacob, Chris G, Jeans, Julia, Johnson, Kimberly J, Kamaliddin, Claire, Kamau, Edwin, Keatley, Jon, Kochakarn, Theerarat, Konate, Drissa S, Konaté, Abibatou, Kone, Aminatou, Kwiatkowski, Dominic P, Kyaw, Myat P, Kyle, Dennis, Lawniczak, Mara, Lee, Samuel K, Lemnge, Martha, Lim, Pharath, Lon, Chanthap, Loua, Kovana M, Mandara, Celine I, Marfurt, Jutta, Marsh, Kevin, Maude, Richard James, Mayxay, Mayfong, Maïga-Ascofaré, Oumou, Miotto, Olivo, Mita, Toshihiro, Mobegi, Victor, Mohamed, Abdelrahim Osman, Mokuolu, Olugbenga A, Montgomery, Jaqui, Morang'a, Collins Misita, Mueller, Ivo, Murie, Kathryn, Newton, Paul N, Ngo Duc, Thang, Nguyen, Thuy, Nguyen, Thuy-Nhien, Nguyen Thi Kim, Tuyen, Nguyen Van, Hong, Noedl, Harald, Nosten, Francois, Noviyanti, Rintis, Ntui, Vincent Ntui-Njock, Nzila, Alexis, Ochola-Oyier, Lynette Isabella, Ocholla, Harold, Oduro, Abraham, Omedo, Irene, Onyamboko, Marie A, Ouedraogo, Jean-Bosco, Oyebola, Kolapo, Oyibo, Wellington Aghoghovwia, Pearson, Richard, Peshu, Norbert, Phyo, Aung P, Plowe, Christopher V, Price, Ric N, Pukrittayakamee, Sasithon, Quang, Huynh Hong, Randrianarivelojosia, Milijaona, Rayner, Julian C, Ringwald, Pascal, Rosanas-Urgell, Anna, Rovira-Vallbona, Eduard, Ruano-Rubio, Valentin, Ruiz, Lastenia, Saunders, David, Shayo, Alex, Siba, Peter, Simpson, Victoria J, Sissoko, Mahamadou S, Smith, Christen, Su, Xin-Zhuan, Sutherland, Colin, Takala-Harrison, Shannon, Talman, Arthur, Tavul, Livingstone, Thanh, Ngo Viet, Thathy, Vandana, Thu, Aung Myint, Toure, Mahamoudou, Tshefu, Antoinette, Verra, Federica, Vinetz, Joseph, Wellems, Thomas E, Wendler, Jason, White, Nicholas J, Whitton, Georgia, Yavo, William, Van Der Pluijm, Rob W, Amenga-Etego, Lucas [0000-0003-4468-0506], Anderson, Tim [0000-0002-0191-0204], Ansah, Patrick O [0000-0002-3214-5621], Ashley, Elizabeth [0000-0002-7620-4822], Ba, Hampate [0000-0002-9299-5775], Baraka, Vito [0000-0001-9694-9293], Bejon, Philip [0000-0002-2135-7549], Bertin, Gwladys I [0000-0002-2218-9591], Boni, Maciej F [0000-0002-0830-9630], Bousema, Teun [0000-0003-2666-094X], Chookajorn, Thanat [0000-0003-2876-6203], Claessens, Antoine [0000-0002-4277-0914], Conway, David J [0000-0002-8711-3037], Craig, Alister [0000-0003-0914-6164], D'Alessandro, Umberto [0000-0001-6341-5009], Day, Nicholas [0000-0003-2309-1171], Diakite, Mahamadou [0000-0002-4268-8857], Djimde, Abdoulaye [0000-0003-0062-2283], Dondorp, Arjen [0000-0001-5190-2395], Drakeley, Chris [0000-0003-4863-075X], Echeverry, Diego F [0000-0003-0301-4478], Erko, Berhanu [0000-0003-1685-752X], Faiz, Abdul [0000-0002-3460-7535], Fanello, Caterina A [0000-0003-1932-9562], Gamboa, Dionicia [0000-0002-1420-7729], Golassa, Lemu [0000-0002-1216-8711], Healy, Sara Anne [0000-0003-3078-6094], Ishengoma, Deus [0000-0003-2040-3416], Jackson, Scott A [0000-0002-3172-1607], Kamaliddin, Claire [0000-0001-8198-6235], Kamau, Edwin [0000-0002-5761-7883], Konate, Drissa S [0000-0002-4177-9642], Kwiatkowski, Dominic P [0000-0002-5023-0176], Kyle, Dennis [0000-0002-0238-965X], Lawniczak, Mara [0000-0002-3006-2080], Loua, Kovana M [0000-0003-0571-0944], Marsh, Kevin [0000-0001-8377-5466], Mayxay, Mayfong [0000-0002-6056-4516], Miotto, Olivo [0000-0001-8060-6771], Mita, Toshihiro [0000-0001-8180-2344], Mobegi, Victor [0000-0002-1962-5583], Morang'a, Collins Misita [0000-0002-6988-150X], Nguyen, Thuy-Nhien [0000-0002-4101-5706], Nosten, Francois [0000-0002-7951-0745], Ntui, Vincent Ntui-Njock [0000-0002-7532-9930], Oduro, Abraham [0000-0002-4191-7419], Onyamboko, Marie A [0000-0002-7501-5931], Ouedraogo, Jean-Bosco [0000-0003-0412-8733], Oyebola, Kolapo [0000-0002-1003-2570], Pearson, Richard [0000-0002-7386-3566], Phyo, Aung P [0000-0002-0383-9624], Price, Ric N [0000-0003-2000-2874], Rayner, Julian C [0000-0002-9835-1014], Rosanas-Urgell, Anna [0000-0002-0432-5203], Shayo, Alex [0000-0002-7099-8537], Su, Xin-Zhuan [0000-0003-3246-3248], Vinetz, Joseph [0000-0001-8344-2004], Wellems, Thomas E [0000-0003-3899-8454], and Apollo - University of Cambridge Repository

Subjects
data resource, plasmodium falciparum, genomics, malaria, genomic epidemiology
Abstract

We describe the MalariaGEN Pf7 data resource, the seventh release of Plasmodium falciparum genome variation data from the MalariaGEN network. It comprises over 20,000 samples from 82 partner studies in 33 countries, including several malaria endemic regions that were previously underrepresented. For the first time we include dried blood spot samples that were sequenced after selective whole genome amplification, necessitating new methods to genotype copy number variations. We identify a large number of newly emerging crt mutations in parts of Southeast Asia, and show examples of heterogeneities in patterns of drug resistance within Africa and within the Indian subcontinent. We describe the profile of variations in the C-terminal of the csp gene and relate this to the sequence used in the RTS,S and R21 malaria vaccines. Pf7 provides high-quality data on genotype calls for 6 million SNPs and short indels, analysis of large deletions that cause failure of rapid diagnostic tests, and systematic characterisation of six major drug resistance loci, all of which can be freely downloaded from the MalariaGEN website.

Published
2023

21. Additional file 2 of Efficacy and safety of pyronaridine–artesunate versus artemether–lumefantrine in the treatment of acute uncomplicated malaria in children in South-West Nigeria: an open-labelled randomized controlled trial

Author

Falade, Catherine O., Orimadegun, Adebola E., Olusola, Fiyinfoluwa I., Michael, Obaro S., Anjorin, Oluwafunmibi E., Funwei, Roland I., Adedapo, Aduragbenro D., Olusanya, Abiola L., Orimadegun, Bose E., and Mokuolu, Olugbenga A.

Abstract

Additional file 2. Table S3: Tables S3a and S3b showing gametocyte carriage among children treated with artemether–lumefantrine and pyronaridine–artesunate during the study.

Published
2023
Full Text
View/download PDF

22. Additional file 1 of Efficacy and safety of pyronaridine–artesunate versus artemether–lumefantrine in the treatment of acute uncomplicated malaria in children in South-West Nigeria: an open-labelled randomized controlled trial

Author

Falade, Catherine O., Orimadegun, Adebola E., Olusola, Fiyinfoluwa I., Michael, Obaro S., Anjorin, Oluwafunmibi E., Funwei, Roland I., Adedapo, Aduragbenro D., Olusanya, Abiola L., Orimadegun, Bose E., and Mokuolu, Olugbenga A.

Abstract

Additional file 1. Table S1: Paired sample genotyping data. Tables S1a–S1h and Tables S2a–S2h and Figs. S1–S8 of results showing liver enzymes, serum bilirubin, urea, creatinine, glucose and glucose of children enrolled in the study.

Published
2023
Full Text
View/download PDF

23. A Randomized Trial to Compare the Safety, Tolerability, and Effectiveness of 3 Antimalarial Regimens for the Prevention of Malaria in Nigerian Patients With Sickle Cell Disease

Author

Olaosebikan, Rasaq, Ernest, Kolade, Bojang, Kalifa, Mokuolu, Olugbenga, Rehman, Andrea M., Affara, Muna, Nwakanma, Davis, Kiechel, Jean-René, Ogunkunle, Taofik, Olagunju, Tope, Murtala, Rukayat, Omefe, Peter, Lambe, Tosin, Bello, Surajudeen, Ibrahim, Olayinka, Olorunsola, Benedict, Ojuawo, Ayotade, Greenwood, Brian, and Milligan, Paul

Published
2015

25. Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria

Author

Tindana, Paulina, primary, Guissou, Rosemonde, additional, Bolarinwa, Oladimeji Akeem, additional, Tou, Fatoumata, additional, de Haan, Freek, additional, Dhorda, Mehul, additional, Dondorp, Arjen M., additional, Amaratunga, Chanaki, additional, Mokuolu, Olugbenga Ayodeji, additional, Ouedraogo, Jean Bosco, additional, and Cheah, Phaik Yeong, additional

Published
2022
Full Text
View/download PDF

26. Malaria

Author

White, Nicholas J, Pukrittayakamee, Sasithon, Hien, Tran Tinh, Faiz, M Abul, Mokuolu, Olugbenga A, and Dondorp, Arjen M

Published
2014
Full Text
View/download PDF

28. A framework for stakeholder engagement in the adoption of new anti-malarial treatments in Africa: a case study of Nigeria.

Author

Mokuolu, Olugbenga Ayodeji, Bolarinwa, Oladimeji Akeem, Opadiran, Oluwatumobi Racheal, Ameen, Hafsat Abolore, Dhorda, Mehul, Cheah, Phaik Yeong, Amaratunga, Chanaki, de Haan, Freek, Tindana, Paulina, and Dondorp, Arjen M.

Subjects
*STAKEHOLDER analysis, *DRUG efficacy, *PRENATAL care, *ARTEMISININ, *COMMUNITIES
Abstract

Background: Recent reports of artemisinin partial resistance from Rwanda and Uganda are worrisome and suggest a future policy change to adopt new anti-malarials. This is a case study on the evolution, adoption, and implementation of new anti-malarial treatment policies in Nigeria. The main objective is to provide perspectives to enhance the future uptake of new anti-malarials, with an emphasis on stakeholder engagement strategies. Methods: This case study is based on an analysis of policy documents and stakeholders' perspectives drawn from an empirical study conducted in Nigeria, 2019–2020. A mixed methods approach was adopted, including historical accounts, review of programme and policy documents, and 33 qualitative in-depth interviews and 6 focus group discussions. Results: Based on policy documents reviewed, the adoption of artemisinin-based combination therapy (ACT) in Nigeria was swift due to political will, funding and support from global developmental partners. However, the implementation of ACT was met with resistance from suppliers, distributors, prescribers, and end-users, attributed to market dynamics, costs and inadequate stakeholder engagement. Deployment of ACT in Nigeria witnessed increased developmental partner support, robust data generation, ACT case-management strengthening and evidence on anti-malarial use in severe malaria and antenatal care management. A framework for effective stakeholder engagement for the future adoption of new anti-malarial treatment strategies was proposed. The framework covers the pathway from generating evidence on drug efficacy, safety and uptake; to making treatment accessible and affordable to end-users. It addresses which stakeholders to engage with and the content of engagement strategies with key stakeholders at different levels of the transition process. Conclusion: Early and staged engagement of stakeholders from global bodies to community level end-users is critical to the successful adoption and uptake of new anti-malarial treatment policies. A framework for these engagements was proposed as a contribution to enhancing the uptake of future anti-malarial strategies. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. Clinical illness and outcomes in Nigerian children with persistent early-appearing anaemia following initiation of artemisinin-based combination treatments of uncomplicated falciparum malaria

Author

Akano Kazeem, Fatunmbi Bayo, Ntadom Godwin, Ayede Adejumoke I., Aderoyeje Temitope, Bakre Adewale, Alebiosu Omobolaji T., Akpoborie Odafe, Okafor Chukwuebuka, Gbotosho Grace O., Folarin Onikepe A., Ebenebe Joy C., Ambe Jose, Wammanda Robinson, Jiya Nma, Finomo Finomo, Emechebe George, Mokuolu Olugbenga, Agomo Chimere, Oguche Stephen, Happi Christian, and Sowunmi Akintunde

Subjects
Persistent early-appearing anaemia, Falciparum malaria, Artemisinin-based combination treatments, Children, Nigeria, Infectious and parasitic diseases, RC109-216
Abstract

In non-anaemic children with malaria, early-appearing anaemia (EAA) is common following artemisinin-based combination treatments (ACTs) and it may become persistent (PEAA). The factors contributing to and kinetics of resolution of the deficit in haematocrit from baseline (DIHFB) characteristic of ACTs-related PEAA were evaluated in 540 consecutive children with malaria treated with artemether-lumefantrine, artesunate-amodiaquine or dihydroartemisinin-piperaquine. Asymptomatic PEAA occurred in 62 children. In a multiple logistic regression model, a duration of illness ≤3 days before presentation, haematocrit

Published
2019
Full Text
View/download PDF

31. Anti-gametocyte antigen humoral immunity and gametocytemia during treatment of uncomplicated falciparum malaria:A multi-national study

Author

O'Flaherty, Katherine, Chan, Jo-Anne, Cutts, Julia C, Zaloumis, Sophie G, Ashley, Elizabeth A, Phyo, Aung Pyae, Drew, Damien R, Dondorp, Arjen M, Day, Nicholas P, Dhorda, Mehul, Fairhurst, Rick M, Lim, Pharath, Amaratunga, Chanaki, Pukrittayakamee, Sasithon, Hien, Tran Tinh, Htut, Ye, Mayxay, Mayfong, Faiz, M Abul, Mokuolu, Olugbenga A, Onyamboko, Marie A, Fanello, Caterina, Takashima, Eizo, Tsuboi, Takafumi, Theisen, Michael, Nosten, Francois, Beeson, James G, Simpson, Julie A, White, Nicholas J, Fowkes, Freya J I, O'Flaherty, Katherine, Chan, Jo-Anne, Cutts, Julia C, Zaloumis, Sophie G, Ashley, Elizabeth A, Phyo, Aung Pyae, Drew, Damien R, Dondorp, Arjen M, Day, Nicholas P, Dhorda, Mehul, Fairhurst, Rick M, Lim, Pharath, Amaratunga, Chanaki, Pukrittayakamee, Sasithon, Hien, Tran Tinh, Htut, Ye, Mayxay, Mayfong, Faiz, M Abul, Mokuolu, Olugbenga A, Onyamboko, Marie A, Fanello, Caterina, Takashima, Eizo, Tsuboi, Takafumi, Theisen, Michael, Nosten, Francois, Beeson, James G, Simpson, Julie A, White, Nicholas J, and Fowkes, Freya J I

Abstract

Introduction: Understanding the human immune response to Plasmodium falciparum gametocytes and its association with gametocytemia is essential for understanding the transmission of malaria as well as progressing transmission blocking vaccine candidates.Methods: In a multi-national clinical efficacy trial of artemisinin therapies (13 sites of varying transmission over South-East Asia and Africa), we measured Immunoglobulin G (IgG) responses to recombinant P. falciparum gametocyte antigens expressed on the gametocyte plasma membrane and leading transmission blocking vaccine candidates Pfs230 (Pfs230c and Pfs230D1M) and Pfs48/45 at enrolment in 1,114 participants with clinical falciparum malaria. Mixed effects linear and logistic regression were used to determine the association between gametocyte measures (gametocytemia and gametocyte density) and antibody outcomes at enrolment.Results: Microscopy detectable gametocytemia was observed in 11% (127/1,114) of participants at enrolment, and an additional 9% (95/1,114) over the follow-up period (up to day 42) (total 20% of participants [222/1,114]). IgG levels in response to Pfs230c, Pfs48/45 and Pfs230D1M varied across study sites at enrolment (p < 0.001), as did IgG seroprevalence for anti-Pfs230c and D1M IgG (p < 0.001), but not for anti-Pfs48/45 IgG (p = 0.159). In adjusted analyses, microscopy detectable gametocytemia at enrolment was associated with an increase in the odds of IgG seropositivity to the three gametocyte antigens (Pfs230c OR [95% CI], p: 1.70 [1.10, 2.62], 0.017; Pfs48/45: 1.45 [0.85, 2.46], 0.174; Pfs230D1M: 1.70 [1.03, 2.80], 0.037), as was higher gametocyte density at enrolment (per two-fold change in gametocyte density Pfs230c OR [95% CI], p: 1.09 [1.02, 1.17], 0.008; Pfs48/45: 1.05 [0.98, 1.13], 0.185; Pfs230D1M: 1.07 [0.99, 1.14], 0.071).Conclusion: Pfs230 and Pfs48/45 antibodies are naturally immunogenic targets associated with patent gametocytemia and increasing gam

Published
2022

32. Genetic architecture of artemisinin-resistant Plasmodium falciparum

Author

Miotto, Olivo, Amato, Roberto, Ashley, Elizabeth A, MacInnis, Bronwyn, Almagro-Garcia, Jacob, Amaratunga, Chanaki, Lim, Pharath, Mead, Daniel, Oyola, Samuel O, Dhorda, Mehul, Imwong, Mallika, Woodrow, Charles, Manske, Magnus, Stalker, Jim, Drury, Eleanor, Campino, Susana, Amenga-Etego, Lucas, Thanh, Thuy-Nhien Nguyen, Tran, Hien Tinh, Ringwald, Pascal, Bethell, Delia, Nosten, Francois, Phyo, Aung Pyae, Pukrittayakamee, Sasithon, Chotivanich, Kesinee, Chuor, Char Meng, Nguon, Chea, Suon, Seila, Sreng, Sokunthea, Newton, Paul N, Mayxay, Mayfong, Khanthavong, Maniphone, Hongvanthong, Bouasy, Htut, Ye, Han, Kay Thwe, Kyaw, Myat Phone, Faiz, Md Abul, Fanello, Caterina I, Onyamboko, Marie, Mokuolu, Olugbenga A, Jacob, Christopher G, Takala-Harrison, Shannon, Plowe, Christopher V, Day, Nicholas P, Dondorp, Arjen M, Spencer, Chris C A, McVean, Gilean, Fairhurst, Rick M, White, Nicholas J, and Kwiatkowski, Dominic P

Published
2015
Full Text
View/download PDF

33. Predicting the Clinical Outcome of Severe Falciparum Malaria in African Children: Findings From a Large Randomized Trial

Author

von Seidlein, Lorenz, Olaosebikan, Rasaq, Hendriksen, Ilse C. E., Lee, Sue J., Adedoyin, Olanrewaju Timothy, Agbenyega, Tsiri, Nguah, Samuel Blay, Bojang, Kalifa, Deen, Jacqueline L., Evans, Jennifer, Fanello, Caterina I., Gomes, Ermelinda, Pedro, Alínia José, Kahabuka, Catherine, Karema, Corine, Kivaya, Esther, Maitland, Kathryn, Mokuolu, Olugbenga A., Mtove, George, Mwanga-Amumpaire, Juliet, Nadjm, Behzad, Nansumba, Margaret, Ngum, Wirichada Pan, Onyamboko, Marie A., Reyburn, Hugh, Sakulthaew, Tharisara, Silamut, Kamolrat, Tshefu, Antoinette K., Umulisa, Noella, Gesase, Samwel, Day, Nicholas P. J., White, Nicholas J., and Dondorp, Arjen M.

Published
2012
Full Text
View/download PDF

34. Appraising Neonatal Morbidity and Mortality in a Developing Country Categorized by Gestational Age Grouping and Implications for Targeted Interventions

Author

Mokuolu, Olugbenga Ayodeji, primary, Adesiyun, Omotayo Oluwakemi, additional, Ibrahim, Olayinka Rasheed, additional, Suberu, Habibat Dirisu, additional, Ibrahim, Selimat, additional, Bello, Surajudeen Oyeleke, additional, Mokikan, Moboni, additional, Obasa, Temitope Olorunshola, additional, and Abdulkadir, Mohammed Baba, additional

Published
2022
Full Text
View/download PDF

35. Drivers of long-lasting insecticide-treated net utilisation and parasitaemia among under-five children in 13 States with high malaria burden in Nigeria

Author

Uhomoibhi, Perpetua, primary, Okoronkwo, Chukwu, additional, Ajayi, IkeOluwapo O., additional, Mokuolu, Olugbenga, additional, Maikore, Ibrahim, additional, Fagbamigbe, Adeniyi, additional, Akinyemi, Joshua O., additional, Okoh, Festus, additional, Ademu, Cyril, additional, Kawu, Issa, additional, Kalambo, Jo-Angeline, additional, and Ssekitooleko, James, additional

Published
2022
Full Text
View/download PDF

36. Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study

Author

O’Flaherty, Katherine, primary, Chan, Jo-Anne, additional, Cutts, Julia C., additional, Zaloumis, Sophie G., additional, Ashley, Elizabeth A., additional, Phyo, Aung Pyae, additional, Drew, Damien R., additional, Dondorp, Arjen M., additional, Day, Nicholas P., additional, Dhorda, Mehul, additional, Fairhurst, Rick M., additional, Lim, Pharath, additional, Amaratunga, Chanaki, additional, Pukrittayakamee, Sasithon, additional, Hien, Tran Tinh, additional, Htut, Ye, additional, Mayxay, Mayfong, additional, Faiz, M. Abul, additional, Mokuolu, Olugbenga A., additional, Onyamboko, Marie A., additional, Fanello, Caterina, additional, Takashima, Eizo, additional, Tsuboi, Takafumi, additional, Theisen, Michael, additional, Nosten, Francois, additional, Beeson, James G., additional, Simpson, Julie A., additional, White, Nicholas J., additional, and Fowkes, Freya J. I., additional

Published
2022
Full Text
View/download PDF

37. Molecular profiling of the artemisinin resistance Kelch 13 gene in Plasmodium falciparum from Nigeria

Author

Ajogbasile, Fehintola V., primary, Oluniyi, Paul E., additional, Kayode, Adeyemi T., additional, Akano, Kazeem O., additional, Adegboyega, Benjamin B., additional, Philip, Courage, additional, Ogbulafor, Nnenna, additional, Okafor, Henrietta U., additional, Oguche, Stephen, additional, Wammanda, Robinson D., additional, Mokuolu, Olugbenga A., additional, Folarin, Onikepe A., additional, and Happi, Christian T., additional

Published
2022
Full Text
View/download PDF

39. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial

Author

Dondorp, Arjen M, Fanello, Caterina I, Hendriksen, Ilse CE, Gomes, Ermelinda, Seni, Amir, Chhaganlal, Kajal D, Bojang, Kalifa, Olaosebikan, Rasaq, Anunobi, Nkechinyere, Maitland, Kathryn, Kivaya, Esther, Agbenyega, Tsiri, Nguah, Samuel Blay, Evans, Jennifer, Gesase, Samwel, Kahabuka, Catherine, Mtove, George, Nadjm, Behzad, Deen, Jacqueline, Mwanga-Amumpaire, Juliet, Nansumba, Margaret, Karema, Corine, Umulisa, Noella, Uwimana, Aline, Mokuolu, Olugbenga A, Adedoyin, Olanrewaju T, Johnson, Wahab BR, Tshefu, Antoinette K, Onyamboko, Marie A, Sakulthaew, Tharisara, Ngum, Wirichada Pan, Silamut, Kamolrat, Stepniewska, Kasia, Woodrow, Charles J, Bethell, Delia, Wills, Bridget, Oneko, Martina, Peto, Tim E, von Seidlein, Lorenz, Day, Nicholas PJ, and White, Nicholas J

Published
2010
Full Text
View/download PDF

40. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries

Author

Michael Abiola Okunlola, Hugo Gamerro, Adedapo Babatunde Anibaba Ande, Mohammad Tarek Azad, Zahida Qureshi, Begum Nasrin, Sumia Bari, Janna Patterson, Khalid Yunis, Gulshan Ara, Adesina Lawrence Akintan, Manjunath S. Somannavar, Geetanjali Katageri, Soofia Khatoon, Shazia Memon, Olubukola A. Adesina, Omotayo Adesiyun, Preeti Patil, Raheel Sikander, Saima Zulfiqar, Rasmita S. Nayak, Rasheda Khanam, Olorunfemi Oludele Owa, Olateju Eyinade Kudirat, Aboyeji Abiodun Peter, Adebanjo Babalola Adeyemi, Veena Herekar, Adejumoke I. Ayede, Faiza Nassir, Odiah Violet, Salahuddin Ahmed, Adelaide Barassa, Adetokunbo Fabamwo, Madhusmita J. Pradhan, Dilip Kumar Bhowmik, Meagan Harrison, Alfred Osoti, Shahana Ferdous Choudhury, Oluwakemi Funmilola Ashubu, Fredrick Were, Francis Bola Akinkunmi, M. M. Patil, Sadia Zulfiqar, Waweru Salome, Hafsa Mohamed, Mojibur Rahman, Harish Chellani, Adegoke Gbadegesin Falade, Elizabeth Disu, Probhat Ranjan Dey, Sujata S. Misra, Anthony Dennis Isah, Bankole Peter Kuti, Liana Campodonico, Saleha Begum Chowdhury, Olusanya Abiodun, Sangappa M. Dhaded, Shaheen Akter, Bukola Fawole, Olufemi M. Omololu, Mrityunjay C Metgud, Anjuman Ara, Sangamesh Mathpati, M. A. Matin, Aloysius Ebedi, Saumya S. Nanda, Umesh Ramdurg, Lumaan Sheikh, Bernard Gwer, Grace Ochieng, Ireti Patricia Eniowo, Vishwanath L. Machakanur, Gilda Piaggio, Nazma Begum, Guillermo Carroli, Jamal Anwar, Ejinkeonye I. Kate, Murshed Ahmed Chowdhury, Kidza Mugerwa, Zainab Imam, John Kinuthia, Saima Sultana, Abdus Sabur, Mubarak Ali, Ebunoluwa A. Adejuyigbe, Shruti S. Andola, Shabina Ariff, A Metin Gülmezoglu, Bernadine Lusweti, Daniel Giordano, Farida Yasmin, Ashalata A. Mallapur, Olusola Comfort Famurewa, James Neilson, Mohammad Abdul Mannan, Shazia Rani, Sumangala Math, Sunil S Vernekar, Lucy Das, Bhavana B. Lakhkar, Nayarit Mohamed, Mokuolu Olugbenga, Hadiza Abdulaziz Idris, Omolayo Adebukola Olubosede, Shivaprasad Goudar, Joshua P. Vogel, My Huong Nguyen, George Gwako, Wilfred Sanni, Shailaja R. Bidri, Lawal Oyeneyin, Elizabeth Molyneux, Sajid Soofi, Joachim Ogindo, Rajiv Bahl, Salma Sheikh, Ikechukwu Okonkwo, Abdullah H. Baqui, Henry Chineme Anyabolu, Mohammod Shahidullah, Shailaja Bidri, Ekwem Lilian Osaretin, Maya Padhi, Olugbenga Runsewe, Akintunde Olusegun Fehintola, Yeshita V. Pujar, Bhuvaneshwari C. Yelamali, Fatima Ali Sallau, Oluwafemi Kuti, Fernando Althabe, Leena B. Das, Nida Najimi, Okoli Chinyere Viola, Muttu R. Gudadinni, Olabanke Rosena Oluwafemi, Frederick Were, Ibraheem Olayemi Awowole, Sujata Misra, Ramesh Pol, Olabisi Florence Dedeke, Njoroge John Githua, Olubunmi Busari, Sajid Bashir Soofi, Ahmed Laving, Shivaprasad S. Goudar, Girija Shankar G. Mohanty, Theresa Azonima Irinyenikan, Bipsha S. Singh, Olufemi T Oladapo, and Ebunoluwa Aderonke Adejuyigbe

Subjects
Pediatrics, medicine.medical_specialty, Low resource, Medicine (miscellaneous), Placebo, World Health Organization, World health, Dexamethasone, law.invention, Double blind, Study Protocol, Randomized controlled trial, Double-Blind Method, law, Pregnancy, Medicine, Humans, Pharmacology (medical), Multi centre, lcsh:R5-920, business.industry, Prenatal Care, Action (philosophy), Health Resources, Premature Birth, Female, business, lcsh:Medicine (General), Infant, Premature, Multi country
Abstract

Background Antenatal corticosteroids (ACS) have long been regarded as a cornerstone intervention in mitigating the adverse effects of a preterm birth. However, the safety and efficacy of ACS in hospitals in low-resource countries has not been established in an efficacy trial despite their widespread use. Findings of a large cluster-randomized trial in six low- and middle-income countries showed that efforts to scale up ACS use in low-resource settings can lead to harm. There is equipoise regarding the benefits and harms of ACS use in hospitals in low-resource countries. This randomized controlled trial aims to determine whether ACS are safe and efficacious when given to women at risk of imminent birth in the early preterm period, in hospitals in low-resource countries. Methods/design The trial design is a parallel, two-arm, double-blind, individually randomized, placebo-controlled trial of ACS (dexamethasone) for women at risk of imminent preterm birth. The trial will recruit 6018 women in participating hospitals across five low-resource countries (Bangladesh, India, Kenya, Nigeria and Pakistan). The primary objectives are to compare the efficacy of dexamethasone with placebo on survival of the baby and maternal infectious morbidity. The primary outcomes are: 1) neonatal death (to 28 completed days of life); 2) any baby death (any stillbirth postrandomization or neonatal death); and 3) a composite outcome to assess possible maternal bacterial infections. The trial will recruit eligible, consenting pregnant women from 26 weeks 0 days to 33 weeks 6 days gestation with confirmed live fetuses, in whom birth is planned or expected within 48 h. The intervention comprises a regimen of intramuscular dexamethasone sodium phosphate. The comparison is an identical placebo regimen (normal saline). A total of 6018 women will be recruited to detect a reduction of 15% or more in neonatal deaths in a two-sided 5% significance test with 90% power (including 10% loss to follow-up). Discussion Findings of this trial will guide clinicians, programme managers and policymakers on the safety and efficacy of ACS in hospitals in low-resource countries. The trial findings will inform updating of the World Health Organization’s global recommendations on ACS use. Trial registration ACTRN12617000476336. Registered on 31 March 2017. Electronic supplementary material The online version of this article (10.1186/s13063-019-3488-z) contains supplementary material, which is available to authorized users.

Published
2019

41. To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?

Author

de Haan, Freek, primary, Bolarinwa, Oladimeji Akeem, additional, Guissou, Rosemonde, additional, Tou, Fatoumata, additional, Tindana, Paulina, additional, Boon, Wouter P. C., additional, Moors, Ellen H. M., additional, Cheah, Phaik Yeong, additional, Dhorda, Mehul, additional, Dondorp, Arjen M., additional, Ouedraogo, Jean Bosco, additional, Mokuolu, Olugbenga A., additional, and Amaratunga, Chanaki, additional

Published
2021
Full Text
View/download PDF

42. Strengthening retinopathy of prematurity screening and treatment services in Nigeria: a case study of activities, challenges and outcomes 2017-2020

Author

Ademola-Popoola, Dupe S, primary, Fajolu, Iretiola B, additional, Gilbert, Clare, additional, Olusanya, Bolutife A, additional, Onakpoya, Oluwatoyin H, additional, Ezisi, Chinyelu N, additional, Musa, Kareem O, additional, Chan, Robison Vernon Paul, additional, Okeigbemen, Valentina W, additional, Muhammad, Rilwan C, additional, Malik, Aeesha N J, additional, Adio, Adedayo O, additional, Bodunde, Olubunmi T, additional, Rafindadi, Abdulkadir L, additional, Oluleye, Tunji S, additional, Tongo, Olukemi O, additional, Badmus, Sarat A, additional, Adebara, Olufunmilayo V, additional, Padhi, Tapas Ranjan, additional, Ezenwa, Beatrice N, additional, Obajolowo, Tokunbo S, additional, Olokoba, Lateefat B, additional, Olatunji, Victoria A, additional, Babalola, Yewande Olubunmi, additional, Ugalahi, Mary O, additional, Adenekan, Adetunji, additional, Adesiyun, Omotayo O, additional, Sahoo, Jagdish, additional, Miller, Marilyn T, additional, Uhumwangho, Odarosa M, additional, Olagbenro, Adeduntan S, additional, Adejuyigbe, Ebunoluwa A, additional, Ezeaka, Chinyere V C, additional, Mokuolu, Olugbenga, additional, Ogunlesi, Tinuade A, additional, Ogunfowora, Olusoga B, additional, Abdulkadir, Isa, additional, Abdullahi, Fatima L, additional, Fabiyi, Abosede T, additional, Hassan, Laila H L, additional, Baiyeroju, Aderonke M, additional, Opara, Peace I, additional, Oladigbolu, Kehinde, additional, Eneh, Augusta U, additional, Fiebai, Bassey E, additional, Mahmud-Ajeigbe, Fatima A, additional, Peter, Elijah N, additional, and Abdullahi, Hawwa S, additional

Published
2021
Full Text
View/download PDF

44. To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?

Author

de Haan, Freek, Bolarinwa, Oladimeji Akeem, Guissou, Rosemonde, Tou, Fatoumata, Tindana, Paulina, Boon, Wouter P. C., Moors, Ellen H. M., Cheah, Phaik Yeong, Dhorda, Mehul, Dondorp, Arjen M., Ouedraogo, Jean Bosco, Mokuolu, Olugbenga A., Amaratunga, Chanaki, de Haan, Freek, Bolarinwa, Oladimeji Akeem, Guissou, Rosemonde, Tou, Fatoumata, Tindana, Paulina, Boon, Wouter P. C., Moors, Ellen H. M., Cheah, Phaik Yeong, Dhorda, Mehul, Dondorp, Arjen M., Ouedraogo, Jean Bosco, Mokuolu, Olugbenga A., and Amaratunga, Chanaki

Abstract

Introduction Triple artemisinin-based combination therapies (TACTs) are being developed as a response to artemisinin and partner drug resistance in the treatment of falciparum malaria in Southeast Asia. In African countries, where current artemisinin-based combination therapies (ACTs) are still effective, TACTs have the potential to benefit the larger community and future patients by mitigating the risk of drug resistance. This study explores the extent to which the antimalarial drug markets in African countries are ready for a transition to TACTs. Methods A qualitative study was conducted in Nigeria and Burkina Faso and comprised in-depth interviews (n = 68) and focus group discussions (n = 11) with key actor groups in the innovation system of antimalarial therapies. Results Evidence of ACT failure in African countries and explicit support for TACTs by the World Health Organization (WHO) and international funders were perceived important determinants for the market prospects of TACTs in Nigeria and Burkina Faso. At the country level, slow regulatory and implementation procedures were identified as potential barriers towards rapid TACTs deployment. Integrating TACTs in public sector distribution channels was considered relatively straightforward. More challenges were expected for integrating TACTs in private sector distribution channels, which are characterized by patient demand and profit motives. Finally, several affordability and acceptability issues were raised for which ACTs were suggested as a benchmark. Conclusion The market prospects of TACTs in Nigeria and Burkina Faso will depend on the demonstration of the added value of TACTs over ACTs, their advocacy by the WHO, the inclusion of TACTs in financial and regulatory arrangements, and their alignment with current distribution and deployment practices. Further clinical, health-economic and feasibility studies are required to inform decision makers about the broader implications of a transition to TACTs in Afr

Published
2021

45. To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?

Author

Innovation Studies, Innovation and Sustainability, de Haan, Freek, Bolarinwa, Oladimeji Akeem, Guissou, Rosemonde, Tou, Fatoumata, Tindana, Paulina, Boon, Wouter P. C., Moors, Ellen H. M., Cheah, Phaik Yeong, Dhorda, Mehul, Dondorp, Arjen M., Ouedraogo, Jean Bosco, Mokuolu, Olugbenga A., Amaratunga, Chanaki, Innovation Studies, Innovation and Sustainability, de Haan, Freek, Bolarinwa, Oladimeji Akeem, Guissou, Rosemonde, Tou, Fatoumata, Tindana, Paulina, Boon, Wouter P. C., Moors, Ellen H. M., Cheah, Phaik Yeong, Dhorda, Mehul, Dondorp, Arjen M., Ouedraogo, Jean Bosco, Mokuolu, Olugbenga A., and Amaratunga, Chanaki

Published
2021

46. An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples

Author

Ahouidi, Ambroise, Ali, Mozam, Almagro-Garcia, Jacob, Amambua-Ngwa, Alfred, Amaratunga, Chanaki, Amato, Roberto, Amenga-Etego, Lucas, Andagalu, Ben, Anderson, Tim JC, Andrianaranjaka, Voahangy, Apinjoh, Tobias, Ariani, Cristina, Ashley, Elizabeth A, Auburn, Sarah, Awandare, Gordon, Ba, Hampdate, Baraka, Vito, Barry, Alyssa E, Bejon, Philip, Bertin, Gwladys I, Boni, Maciej F, Borrmann, Steffen, Bousema, Teun, Branch, Oralee, Bull, Peter C, Busby, George BJ, Chookajorn, Thanat, Chotivanich, Kesinee, Claessens, Antoine, Conway, David, Craig, Alister, D'Alessandro, Umberto, Dama, Souleymane, Day, Nicholas PJ, Denis, Brigitte, Diakite, Mahamadou, Djimdé, Abdoulaye, Dolecek, Christiane, Dondorp, Arjen M, Drakeley, Chris, Drury, Eleanor, Duffy, Patrick, Echeverry, Diego F, Egwang, Thomas G, Erko, Berhanu, Fairhurst, Rick M, Faiz, Abdul, Fanello, Caterina A, Fukuda, Mark M, Gamboa, Dionica, Ghansah, Anita, Golassa, Lemu, Goncalves, Sonia, Hamilton, William L, Harrison, GL Abby, Hart, Lee, Henrichs, Christa, Hien, Tran Tinh, Hill, Catherine A, Hodgson, Abraham, Hubbart, Christina, Imwong, Mallika, Ishengoma, Deus S, Jackson, Scott A, Jacob, Chris G, Jeffery, Ben, Jeffreys, Anna E, Johnson, Kimberly J, Jyothi, Dushyanth, Kamaliddin, Claire, Kamau, Edwin, Kekre, Mihir, Kluczynski, Krzysztof, Kochakarn, Theerarat, Konaté, Abibatou, Kwiatkowski, Dominic P, Kyaw, Myat Phone, Lim, Pharath, Lon, Chanthap, Loua, Kovana M, Maïga-Ascofaré, Oumou, Malangone, Cinzia, Manske, Magnus, Marfurt, Jutta, Marsh, Kevin, Mayxay, Mayfong, Miles, Alistair, Miotto, Olivo, Mobegi, Victor, Mokuolu, Olugbenga A, Montgomery, Jacqui, Mueller, Ivo, Newton, Paul N, Nguyen, Thuy, Nguyen, Thuy-Nhien, Noedl, Harald, Nosten, Francois, Noviyanti, Rintis, Nzila, Alexis, Ochola-Oyier, Lynette I, Ahouidi, Ambroise, Ali, Mozam, Almagro-Garcia, Jacob, Amambua-Ngwa, Alfred, Amaratunga, Chanaki, Amato, Roberto, Amenga-Etego, Lucas, Andagalu, Ben, Anderson, Tim JC, Andrianaranjaka, Voahangy, Apinjoh, Tobias, Ariani, Cristina, Ashley, Elizabeth A, Auburn, Sarah, Awandare, Gordon, Ba, Hampdate, Baraka, Vito, Barry, Alyssa E, Bejon, Philip, Bertin, Gwladys I, Boni, Maciej F, Borrmann, Steffen, Bousema, Teun, Branch, Oralee, Bull, Peter C, Busby, George BJ, Chookajorn, Thanat, Chotivanich, Kesinee, Claessens, Antoine, Conway, David, Craig, Alister, D'Alessandro, Umberto, Dama, Souleymane, Day, Nicholas PJ, Denis, Brigitte, Diakite, Mahamadou, Djimdé, Abdoulaye, Dolecek, Christiane, Dondorp, Arjen M, Drakeley, Chris, Drury, Eleanor, Duffy, Patrick, Echeverry, Diego F, Egwang, Thomas G, Erko, Berhanu, Fairhurst, Rick M, Faiz, Abdul, Fanello, Caterina A, Fukuda, Mark M, Gamboa, Dionica, Ghansah, Anita, Golassa, Lemu, Goncalves, Sonia, Hamilton, William L, Harrison, GL Abby, Hart, Lee, Henrichs, Christa, Hien, Tran Tinh, Hill, Catherine A, Hodgson, Abraham, Hubbart, Christina, Imwong, Mallika, Ishengoma, Deus S, Jackson, Scott A, Jacob, Chris G, Jeffery, Ben, Jeffreys, Anna E, Johnson, Kimberly J, Jyothi, Dushyanth, Kamaliddin, Claire, Kamau, Edwin, Kekre, Mihir, Kluczynski, Krzysztof, Kochakarn, Theerarat, Konaté, Abibatou, Kwiatkowski, Dominic P, Kyaw, Myat Phone, Lim, Pharath, Lon, Chanthap, Loua, Kovana M, Maïga-Ascofaré, Oumou, Malangone, Cinzia, Manske, Magnus, Marfurt, Jutta, Marsh, Kevin, Mayxay, Mayfong, Miles, Alistair, Miotto, Olivo, Mobegi, Victor, Mokuolu, Olugbenga A, Montgomery, Jacqui, Mueller, Ivo, Newton, Paul N, Nguyen, Thuy, Nguyen, Thuy-Nhien, Noedl, Harald, Nosten, Francois, Noviyanti, Rintis, Nzila, Alexis, and Ochola-Oyier, Lynette I

Abstract

MalariaGEN is a data-sharing network that enables groups around the world to work together on the genomic epidemiology of malaria. Here we describe a new release of curated genome variation data on 7,000 Plasmodium falciparum samples from MalariaGEN partner studies in 28 malaria-endemic countries. High-quality genotype calls on 3 million single nucleotide polymorphisms (SNPs) and short indels were produced using a standardised analysis pipeline. Copy number variants associated with drug resistance and structural variants that cause failure of rapid diagnostic tests were also analysed.  Almost all samples showed genetic evidence of resistance to at least one antimalarial drug, and some samples from Southeast Asia carried markers of resistance to six commonly-used drugs. Genes expressed during the mosquito stage of the parasite life-cycle are prominent among loci that show strong geographic differentiation. By continuing to enlarge this open data resource we aim to facilitate research into the evolutionary processes affecting malaria control and to accelerate development of the surveillance toolkit required for malaria elimination.

Published
2021

47. Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa/Rentabilite de l'artesunate parenteral administre chez les enfants gravement atteints de paludisme en Afrique subsaharienne/Relacion coste-eficacia del artesunato para el tratamiento de ninos con malaria grave en el Africa subsahariana

Author

Lubell, Yoel, Riewpaiboon, Arthorn, Dondorp, Arjen M., von Seidlein, Lorenz, Mokuolu, Olugbenga A., Nansumba, Margaret, Gesase, Samwel, Kent, Alison, Mtove, George, Olaosebikan, Rasaq, Ngum, Wirichada Pan, Fanello, Caterina I., Hendriksen, Ilse, Day, Nicholas P.J., White, Nicholas J., and Yeung, Shunmay

Subjects
Medical care, Cost of, Patients -- Care and treatment, Quinine, Children, Malaria -- Care and treatment, Health, World Health Organization
Abstract

Objective To explore the cost-effectiveness of parenteral artesunate for the treatment of severe malaria in children and its potential impact on hospital budgets. Methods The costs of inpatient care of children with severe malaria were assessed in four of the 11 sites included in the African Quinine Artesunate Malaria Treatment trial, conducted with over 5400 children. The drugs, laboratory tests and intravenous fluids provided to 2300 patients from admission to discharge were recorded, as was the length of inpatient stay, to calculate the cost of inpatient care. The data were matched with pooled clinical outcomes and entered into a decision model to calculate the cost per disability-adjusted life year (DALY) averted and the cost per death averted. Findings The mean cost of treating severe malaria patients was similar in the two study groups: 63.5 United States dollars (US$) (95% confidence interval, Cl: 61.7-65.2) in the quinine arm and US$ 66.5 (95% Cl: 63.7-69.2) in the artesunate arm. Children treated with artesunate had 22.5% lower mortality than those treated with quinine and the same rate of neurological sequelae: (artesunate arm: 2.3 DALYs per patient; quinine arm: 3.0 DALYs per patient). Compared with quinine as a baseline, artesunate showed an incremental cost per DALY averted and an incremental cost per death averted of US$ 3.8 and US$ 123, respectively. Conclusion Artesunate is a highly cost-effective and affordable alternative to quinine for treating children with severe malaria. The budgetary implications of adopting artesunate for routine use in hospital-based care are negligible. Objectif Etudier la rentabilite de l'artesunate parenteral dans le cadre du traitement d'enfants gravement atteints de paludisme et son impact potentiel sur les budgets hospitaliers. Methodes Les couts des soins administres aux patients hospitalises gravement atteints de paludisme ont ete evalues dans 4 des 11 sites participant a l'essai Traitement quinine/artesunate contre le paludisme en Afrique, realise sur plus de 5400 enfants. Afin de calculer le cout de l'hospitalisation, les medicaments, les essais en laboratoire et les liquides intraveineux administres a 2300 patients entre leur admission et leur sortie ont ete enregistres, ainsi que la duree de l'hospitalisation. Les donnees ont ete comparees avec les resultats cliniques regroupes et integres a un modele de decision afin de calculer le cout par annee de vie corrigee du facteur invalidite (AVCI) evite et le cout par deces evite. Resultats Le cout moyen du traitement des patients gravement atteints du paludisme s'est revele similaire dans les deux groupes experimentaux: 63,5 dollars americains (US$) (intervalle de confiance 95% IC: 61,7-65,2) pour le bras recevant la quinine et 66,5 US$ (95% IC: 63,7-69,2) pour le bras recevant l'artesunate. Les enfants traites par artesunate affichaient un taux de mortalite inferieur de 22,5% a ceux recevant de la quinine, et un taux de sequelles neurologiques identique: (bras recevant l'artesunate: 2,3 AVCI par patient; bras recevant la quinine: 3,0 AVCI par patient). En comparaison avec la quinine en tant que ligne de base, l'artesunate a demontre un cout incremental par AVCI evitee et un cout incremental par deces evite de 3,8 US$ et 123 US$, respectivement. Conclusion Dans le cadre du traitement des enfants gravement atteints de paludisme, rartesunate constitue une alternative extremement rentable et abordable par rapport a la quinine. Les implications budgetaires liees a l'adoption de l'artesunate pour une utilisation habituelle Iors des soins hospitaliers sont negligeables. Objetivo Analizar la relacion coste-eficacia del artesunato parenteral en el tratamiento de la malaria grave infantil y su posible impacto en los presupuestos hospitalarios. Metodos En cuatro de los 11 centros incluidos en el Estudio comparativo de los tratamientos de la malaria con artesunato y quinina en Africa participaron mas de 5400 ninos. Para calcular el coste de la hospitalizacion se registraron los farmacos, las pruebas clinicas y los liquidos endovenosos suministrados a 2300 pacientes, desde su ingreso hasta el alta, segun la duracion del ingreso del paciente. Los datos se compararon con los resultados clinicos agrupados e introducidos en un modelo de decision para calcular el coste por ano de vida ajustada por discapacidad (AVAD) evitada y el coste por muerte evitada. Resultados El coste medio del tratamiento de los pacientes con malaria grave fue similar en los dos grupos del estudio: 63,5 dolares estadounidenses (US$) (intervalo de confianza del 95%, IC: 61,7-65,2) en el grupo de quinina y US$ 66,5 (IC del 95%: 63,7-69,2) en el grupo de artesunato. Los ninos tratados con artesunato presentaron una mortalidad un 22,5% inferior que los tratados con quinina y la misma tasa de secuelas neurologicas: (grupo de artesunato: 2,3 AVAD por paciente; grupo de quinina: 3,0 AVAD por paciente). En comparacion con la quinina como referencia, el artesunato ha mostrado un coste incremental por AVAD evitado y un coste incremental por muerte evitada de US$ 3,8 y US$ 123, respectivamente. Conclusion El artesunato es una alternativa a la quinina muy rentable y con una excelente relacion coste-eficacia para el tratamiento de ninos con malaria grave. Las implicaciones presupuestarias de la adopcion del artesunato para su uso sistematico en la asistencia hospitalaria son insignificantes., Introduction Despite reported falling transmission in much of sub-Saharan Africa, (1-3) malaria remains a leading cause of inpatient admissions and mortality in paediatric wards. (4-6) The policy for first-line treatment [...]

Published
2011
Full Text
View/download PDF

48. Spread of Artemisinin Resistance in Plasmodium falciparum Malaria

Author

Ashley, Elizabeth A., Dhorda, Mehul, Fairhurst, Rick M., Amaratunga, Chanaki, Lim, Parath, Suon, Seila, Sreng, Sokunthea, Anderson, Jennifer M., Mao, Sivanna, Sam, Baramey, Sopha, Chantha, Chuor, Char Meng, Nguon, Chea, Sovannaroth, Siv, Pukrittayakamee, Sasithon, Jittamala, Podjanee, Chotivanich, Kesinee, Chutasmit, Kitipumi, Suchatsoonthorn, Chaiyaporn, Runcharoen, Ratchadaporn, Hien, Tran Tinh, Thuy-Nhien, Nguyen Thanh, Thanh, Ngo Viet, Phu, Nguyen Hoan, Htut, Ye, Han, Kay-Thwe, Aye, Kyin Hla, Mokuolu, Olugbenga A., Olaosebikan, Rasaq R., Folaranmi, Olaleke O., Mayxay, Mayfong, Khanthavong, Maniphone, Hongvanthong, Bouasy, Newton, Paul N., Onyamboko, Marie A., Fanello, Caterina I., Tshefu, Antoinette K., Mishra, Neelima, Valecha, Neena, Phyo, Aung Pyae, Nosten, Francois, Yi, Poravuth, Tripura, Rupam, Borrmann, Steffen, Bashraheil, Mahfudh, Peshu, Judy, Faiz, M. Abul, Ghose, Aniruddha, Hossain, M. Amir, Samad, Rasheda, Rahman, M. Ridwanur, Hasan, M. Mahtabuddin, Islam, Akhterul, Miotto, Olivo, Amato, Roberto, MacInnis, Bronwyn, Stalker, Jim, Kwiatkowski, Dominic P., Bozdech, Zbynek, Jeeyapant, Atthanee, Cheah, Phaik Yeong, Sakulthaew, Tharisara, Chalk, Jeremy, Intharabut, Benjamas, Silamut, Kamolrat, Lee, Sue J., Vihokhern, Benchawan, Kunasol, Chanon, Imwong, Mallika, Tarning, Joel, Taylor, Walter J., Yeung, Shunmay, Woodrow, Charles J., Flegg, Jennifer A., Das, Debashish, Smith, Jeffery, Venkatesan, Meera, Plowe, Christopher V., Stepniewska, Kasia, Guerin, Philippe J., Dondorp, Arjen M., Day, Nicholas P., and White, Nicholas J.

Published
2014
Full Text
View/download PDF

49. Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol.

Author

Tindana, Paulina, primary, de Haan, Freek, additional, Mokuolu, Olugbenga Ayodeji, additional, Guissou, Rosemonde, additional, Bolarinwa, Oladimeji Akeem, additional, Ouedraogo, Jean Bosco, additional, Tou, Fatoumata, additional, Boon, Wouter P.C, additional, Moors, Ellen H.M, additional, Dondorp, Arjen M, additional, Dhorda, Mehul, additional, Amaratunga, Chanaki, additional, and Cheah, Phaik Yeong, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results